Legend Biotech (LEGN) Income from Continuing Operations (2019 - 2025)
Legend Biotech (LEGN) posted Income from Continuing Operations of 19700000.0 for Q4 2025, up 48.77% on a QoQ basis from 38457000.0 in Q3 2025, and down 215.6% year-over-year from 17041000.0 in Q4 2024.
Legend Biotech (LEGN) Income from Continuing Operations (2019 - 2025) Analysis & Trends
Legend Biotech's Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 19700000.0 for Q4 2025.
- Quarterly Income from Continuing Operations fell 215.6% year-over-year to 19700000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 279717000.0 (down 58.09% YoY) and the FY2025 annual result came in at 282600000.0, down 59.64% from the prior year.
- Income from Continuing Operations was 19700000.0 for Q4 2025 at Legend Biotech, up from 38457000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 17041000.0 in Q4 2024 and bottomed at 198548000.0 in Q2 2023.
- A 5-year average of 90111450.0 and a median of 91074000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations slumped 32288.91% — and 2024, when it surged 111.75%.
- Legend Biotech's Income from Continuing Operations stood at 84721000.0 in 2021, then sank by 60.2% to 135723000.0 in 2022, then declined by 6.87% to 145042000.0 in 2023, then jumped by 111.75% to 17041000.0 in 2024, then plunged by 215.6% to 19700000.0 in 2025.
- Business Quant data shows LEGN's Income from Continuing Operations at 19700000.0 in Q4 2025, 38457000.0 in Q3 2025, and 124216000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Legend Biotech | 8.26 Bn | 7.36 Bn | - | -19.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -19.70 Mn |
| Sep 30, 2025 | -38.46 Mn |
| Jun 30, 2025 | -124.22 Mn |
| Mar 31, 2025 | -97.34 Mn |
| Dec 31, 2024 | 17.04 Mn |
| Sep 30, 2024 | -116.45 Mn |
| Jun 30, 2024 | -17.74 Mn |
| Mar 31, 2024 | -59.78 Mn |
| Dec 31, 2023 | -145.04 Mn |
| Sep 30, 2023 | -62.78 Mn |
| Jun 30, 2023 | -198.55 Mn |
| Mar 31, 2023 | -111.85 Mn |
| Dec 31, 2022 | -135.72 Mn |
| Sep 30, 2022 | -84.80 Mn |
| Jun 30, 2022 | -192.91 Mn |
| Mar 31, 2022 | -31.96 Mn |
| Dec 31, 2021 | -84.72 Mn |
| Sep 30, 2021 | -124.75 Mn |
| Jun 30, 2021 | -172.38 Mn |
| Mar 31, 2021 | -98,685.00 |